Compugen Ltd. announced recently a collaboration agreement with Merck KGaA, acting for its pharmaceutical division Merck Serono, which covers CGEN-855, a Compugen-discovered novel peptide targeting the FPRL1 G-protein coupled receptor (GPCR).
Life science and healthcare IT consulting company Optra Systems announced in December it has joined the Microsoft Bio-IT Alliance, an association of life science organizations and informatics companies whose focus is to enhance collaboration and accelerate the pace of drug discovery and development.
Roughly seven months after making a second $20 million investment in Isis Pharmaceuticals subsidiary Ibis Biosciences, Abbott announced in December that it would exercise its option to buy the remaining 81.4 percent of the company for an additional $175 million, bringing the total enterprise price to $215 million.
Biocompatibles plc announced in late December it signed product development and option-to-license agreements with AstraZeneca for a proprietary GLP-1 analogue invented and developed by Biocompatibles’ CellMed subsidiary.
Celsion Corp. and Tokyo-based Yakult Honsha Co. Ltd. announced last month definitive agreements relating to the commercialization of Celsion’s proprietary ThermoDox drug delivery platform for the Japanese market.
I’ve never been one to make New Year’s resolutions, but I do see the very beginning of the year as a time to take a look back at what I have accomplished, look forward to the possibilities of a new year and remind myself of the things that are important in this life.
There is an issue between students and professors that I've followed for a long time and been personally engaged in as a student, post-doc, professor and business leader. If a student/post-doc discovers something important using funding secured by the professor in an atmosphere provided by the professor, then how much credit should go to each?